Pirfenidone + Chemotherapy for Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how the drug Pirfenidone, combined with standard chemotherapy, affects individuals with advanced non-small cell lung cancer (NSCLC). Pirfenidone is already used for idiopathic pulmonary fibrosis, but its effects on lung cancer remain unknown. The trial includes two groups: one for squamous cell lung cancer and another for non-squamous cell lung cancer, each receiving a combination of Pirfenidone and chemotherapy (including drugs like Carboplatin and Paclitaxel). This trial may suit those diagnosed with advanced NSCLC who have not yet undergone chemotherapy. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new combination therapy.
Do I have to stop taking my current medications for the trial?
The trial does not specify if you need to stop taking your current medications, but it does exclude participants taking certain medications that affect liver enzymes (CYP1A2 inhibitors). It's best to discuss your current medications with the trial team to see if they might affect your eligibility.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that using pirfenidone with carboplatin-based chemotherapy might be a safe option for treating non-small cell lung cancer (NSCLC). Studies have examined this combination in patients with both lung cancer and idiopathic pulmonary fibrosis, a lung disease that causes scarring. These studies suggest that this treatment is generally well-tolerated.
For those receiving pirfenidone with carboplatin and pemetrexed, the combination seems safe as an initial treatment for the cancer. Similarly, studies indicate that pirfenidone with carboplatin and paclitaxel also appears to be a safe option.
It's important to note that while pirfenidone is approved for another lung condition, it is still being tested for safety in lung cancer treatments. This trial aims to assess how well people tolerate this combination.12345Why do researchers think this study treatment might be promising for lung cancer?
Unlike the standard of care for lung cancer, which typically involves chemotherapy drugs like carboplatin, paclitaxel, and pemetrexed, the investigational treatment combines these with pirfenidone. Pirfenidone is particularly exciting because it is traditionally used to treat lung fibrosis and is believed to have anti-fibrotic and anti-inflammatory properties. Researchers are curious to see if adding pirfenidone can enhance the effectiveness of chemotherapy by potentially reducing tumor growth and improving outcomes for both squamous and non-squamous cell lung cancer patients. This unique approach could offer new hope by tackling the cancer with a dual-action strategy that current treatments don't employ.
What evidence suggests that this trial's treatments could be effective for non-small cell lung cancer?
This trial examines two different treatment combinations for non-small cell lung cancer (NSCLC). One arm combines pirfenidone with carboplatin and pemetrexed, while the other combines pirfenidone with carboplatin and paclitaxel. Studies have shown that pirfenidone with carboplatin-based treatments could be a safe initial option for NSCLC, especially for patients with idiopathic pulmonary fibrosis (IPF). Research suggests that both combinations might be effective and could enhance treatment outcomes for NSCLC. Current evidence supports the potential benefit of these combinations for NSCLC patients.12346
Who Is on the Research Team?
Jhanelle Gray, M.D.
Principal Investigator
H. Lee Moffitt Cancer Center and Research Institute
Are You a Good Fit for This Trial?
This trial is for adults with advanced-stage non-small cell lung cancer (NSCLC) who haven't had chemotherapy for their stage IV disease. They must have good organ function, no severe allergies to the drugs being tested, and not be on certain other medications. Women of childbearing age need a negative pregnancy test and agree to use contraception.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Phase I Dose Escalation
A single center, dose-escalation study of pirfenidone combined with standard chemotherapy to determine the recommended Phase II dose
Phase Ib Dose Expansion
Evaluate early signs of efficacy and obtain more toxicity data with pirfenidone and standard chemotherapy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Carboplatin
- Paclitaxel
- Pemetrexed
- Pirfenidone
Trial Overview
The study tests Pirfenidone combined with standard first-line chemotherapy drugs (Carboplatin, Pemetrexed, Paclitaxel) in patients with NSCLC. Pirfenidone is usually used for a lung condition called IPF but isn't yet approved for NSCLC.
How Is the Trial Designed?
2
Treatment groups
Active Control
Arm B Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus pemetrexed in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
Arm A Combination Therapy: Pirfenidone combined with standard first-line chemotherapy. Participants will receive the combination of Pirfenidone and carboplatin plus paclitaxel in study treatment cycles that last 21 days. Phase 1 Dose Escalation; followed by Phase 1b Dose Expansion.
Carboplatin is already approved in United States, European Union, Canada for the following indications:
- Ovarian cancer
- Testicular cancer
- Lung cancer
- Head and neck cancer
- Brain cancer
- Ovarian cancer
- Small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
H. Lee Moffitt Cancer Center and Research Institute
Lead Sponsor
Citations
Safety and effectiveness of pirfenidone combined with ...
The present study found that pirfenidone combined with carboplatin‐based regimens or ICIs might be safe first‐line chemotherapy for patients with IPF and NSCLC.
Safety and effectiveness of pirfenidone combined with ...
The present study found that pirfenidone combined with carboplatin-based regimens or ICIs might be safe first-line chemotherapy for patients with IPF and NSCLC.
Safety and effectiveness of pirfenidone combined with ...
Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: A pilot study.
Study Details | NCT03177291 | Pirfenidone Combined With ...
The purpose of this study is to find out what effects (good and/or bad) Pirfenidone combined with standard first-line chemotherapy will have on you and ...
The safety and efficacy of weekly paclitaxel in combination ...
Weekly paclitaxel and carboplatin combination chemotherapy was as effective as conventional regimens in advanced NSCLC patients without IIP and was safer than ...
(PDF) Safety and effectiveness of pirfenidone combined ...
Results: Median PFS for lung cancer was 110 days (95% confidence interval [CI]: 57-199 days), while the median OS was 362 days (95% CI: 220-526 ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.